Cystinosis

What is Cystinosis?

Cystinosis is a rare inherited metabolic disorder characterized by the abnormal accumulation of the amino acid cystine within cells throughout the body. This lysosomal storage disease primarily affects the kidneys, eyes, and other organs, causing progressive damage over time. The condition affects approximately 1 in 100,000 to 200,000 people worldwide and follows an autosomal recessive inheritance pattern. Without early diagnosis and treatment, cystinosis can lead to kidney failure and other serious complications, but with proper management, patients can live significantly longer and healthier lives.

Key statistics

Symptoms

The primary symptoms include growth failure, excessive urination and thirst, photophobia, corneal cystine crystals, kidney dysfunction, and hypothyroidism.

Cystinosis symptoms typically appear in the first year of life with the infantile form, which is the most common and severe variant. Early signs include failure to thrive, excessive urination (polyuria), excessive thirst (polydipsia), and feeding difficulties. Children often present with renal Fanconi syndrome, characterized by the kidneys’ inability to reabsorb important nutrients and electrolytes.

Eye-related symptoms develop early and include severe photophobia (light sensitivity) due to cystine crystal deposits in the cornea. These crystals can be seen during eye examination and are pathognomonic for the condition. Without treatment, patients may develop retinal complications and potential vision loss.

Submit Your Paper

Endocrine complications commonly include hypothyroidism, which can further impact growth and development. Many patients also develop diabetes mellitus, delayed puberty, and male infertility. Muscle weakness and swallowing difficulties may emerge as the disease progresses.

Advanced symptoms in untreated patients include chronic kidney disease progressing to end-stage renal failure, typically by age 10-12 years. Neurological complications can include muscle weakness, difficulty swallowing, and in some cases, central nervous system involvement affecting cognitive function.

Causes and risk factors

Cystinosis is caused by mutations in the CTNS gene, which provides instructions for making a protein called cystinosin. This protein functions as a transporter that moves cystine out of lysosomes, the cellular compartments responsible for breaking down waste products. When cystinosin is defective or absent, cystine accumulates within lysosomes throughout the body, forming harmful crystals that damage cells and tissues.

The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutation in the CTNS gene for their child to be affected. Parents of affected children are typically carriers who show no symptoms themselves. The primary risk factor is having two parents who are carriers of CTNS mutations. Consanguineous marriages (between related individuals) increase the risk, as seen in some populations with higher carrier frequencies.

There are no environmental or lifestyle risk factors that contribute to developing cystinosis, as it is purely a genetic condition present from birth.

Prevention

As a genetic disorder, cystinosis cannot be prevented through lifestyle modifications or environmental changes. However, genetic counseling and testing options are available for families with a history of the condition.

Carrier testing can identify individuals who carry one copy of a CTNS mutation, particularly important for family members of affected patients or individuals from populations with higher carrier frequencies. Prenatal testing through chorionic villus sampling or amniocentesis can diagnose cystinosis in developing fetuses when both parents are known carriers.

Preimplantation genetic diagnosis (PGD) is available for couples undergoing in vitro fertilization, allowing selection of embryos without CTNS mutations. Newborn screening programs in some regions include testing for cystinosis, enabling early diagnosis and treatment initiation before irreversible damage occurs.

Complications

Without proper treatment, cystinosis leads to progressive multi-organ dysfunction. The most serious complication is chronic kidney disease, which typically progresses to end-stage renal failure requiring dialysis or kidney transplantation by age 10-12 years in untreated patients.

Endocrine complications include hypothyroidism, diabetes mellitus, hypogonadism, and adrenal insufficiency. Growth failure and delayed puberty are common consequences of both kidney dysfunction and endocrine abnormalities.

Ocular complications progress from corneal crystal deposits and photophobia to potentially sight-threatening retinal involvement, including pigmentary retinopathy and decreased visual acuity. Muscle complications can develop, including myopathy affecting swallowing and breathing muscles.

Neurological complications may include central nervous system involvement, particularly in patients with delayed diagnosis or inadequate treatment. Bone disease and osteoporosis can result from chronic kidney disease and endocrine dysfunction.

Diagnosis

Diagnosis of cystinosis involves multiple approaches, with the gold standard being measurement of cystine levels in white blood cells. Elevated cystine content (typically >2 nmol half-cystine/mg protein) confirms the diagnosis.

Clinical evaluation includes comprehensive assessment of kidney function through blood tests measuring creatinine, blood urea nitrogen, and electrolytes. Urine testing reveals proteinuria, glycosuria, and evidence of renal Fanconi syndrome with excessive loss of amino acids, phosphate, and bicarbonate.

Ophthalmologic examination using slit-lamp microscopy identifies characteristic cystine crystals in the cornea, which appear as refractile deposits throughout the corneal stroma. These crystals are pathognomonic for cystinosis and may be visible even in very young children.

Genetic testing confirms CTNS mutations and can identify the specific variants involved. This information is valuable for family counseling and may have implications for prognosis and treatment response.

Additional tests include thyroid function studies, growth hormone assessment, and monitoring for diabetes mellitus. Kidney biopsy may show characteristic changes but is not typically necessary for diagnosis.

Treatment

The cornerstone of cystinosis treatment is cysteamine, an orphan drug that depletes intracellular cystine levels. Oral cysteamine bitartrate must be taken every six hours around the clock to maintain therapeutic levels. This treatment significantly slows disease progression and preserves kidney function when started early.

Topical cysteamine eye drops treat corneal cystine crystals and reduce photophobia. These drops must be prepared specially and require frequent application throughout the day.

Supportive treatments address specific complications and symptoms. Kidney dysfunction requires management of electrolyte imbalances, metabolic acidosis, and phosphate wasting. Supplementation with phosphate, potassium, carnitine, and sodium bicarbonate may be necessary.

Endocrine replacement therapy includes thyroid hormone for hypothyroidism, growth hormone for growth failure, and insulin for diabetes mellitus. Testosterone or estrogen replacement may be needed for delayed puberty.

Advanced kidney disease may require dialysis or kidney transplantation. Importantly, cysteamine treatment should continue after transplantation to prevent cystine accumulation in other organs.

Delayed-release cysteamine formulations allow less frequent dosing, improving adherence and quality of life while maintaining therapeutic efficacy.

Prognosis

With early diagnosis and consistent cysteamine treatment, the prognosis for cystinosis patients has improved dramatically. Patients starting treatment in infancy can maintain kidney function for decades longer than historical untreated patients, with some maintaining stable kidney function into adulthood.

Without treatment, infantile cystinosis typically leads to end-stage renal failure by age 10-12 years, with significantly shortened life expectancy. Progressive complications affecting multiple organ systems result in substantial morbidity and mortality.

Early treatment initiation, ideally before significant kidney damage occurs, provides the best outcomes. Patients diagnosed through newborn screening programs and treated from early infancy show the most favorable long-term prognosis.

Even with optimal treatment, some complications may still develop over time, but their onset is delayed and severity reduced. Continued research into new treatments offers hope for further improvements in long-term outcomes.

Quality of life

Living with cystinosis requires significant lifestyle adaptations, but many patients achieve good quality of life with proper management. The demanding medication schedule, requiring cysteamine every six hours including nighttime doses, can be challenging for families and patients.

Educational support is often needed due to potential cognitive effects and frequent medical appointments. Many children require individualized education plans accommodating their medical needs and potential learning difficulties.

Physical activity should be encouraged within individual limitations, with attention to hydration needs due to kidney involvement. Regular ophthalmologic care and use of sunglasses help manage photophobia and protect vision.

Psychological support benefits both patients and families coping with this chronic condition. Support groups and connections with other affected families provide valuable emotional support and practical advice.

Transition to adult care requires careful planning and coordination between pediatric and adult specialists. Vocational counseling may help patients identify suitable career paths considering their medical limitations.

Pregnancy and fertility

Fertility is commonly affected in cystinosis patients, particularly males who often experience hypogonadism and infertility due to cystine accumulation in reproductive organs. Females may have irregular menstruation and reduced fertility, though some successful pregnancies have been reported.

For women with cystinosis considering pregnancy, preconception counseling is essential. Kidney function must be stable, and close monitoring throughout pregnancy is required due to increased risk of complications. Cysteamine use during pregnancy requires careful risk-benefit assessment, though some women have successfully continued treatment.

Genetic counseling is crucial since each child of an affected parent has a 100% chance of being a carrier. If the partner is also a carrier, each child has a 25% chance of being affected with cystinosis.

Children

Pediatric management focuses on early diagnosis, prompt treatment initiation, and comprehensive care addressing growth, development, and educational needs. Growth monitoring is essential, with consideration of growth hormone therapy when indicated.

School accommodations may include frequent bathroom breaks due to polyuria, flexible scheduling for medical appointments, and potential academic support. Social support helps children cope with being different from peers due to medication schedules and dietary restrictions.

Family education is crucial for medication compliance and recognizing complications. Adolescent patients require particular support transitioning to self-management of their complex treatment regimen.

When to see a doctor

Immediate medical attention is needed for signs of severe dehydration, persistent vomiting preventing medication absorption, or sudden changes in urination patterns. Emergency evaluation is warranted for breathing difficulties, severe muscle weakness, or signs of kidney failure.

Routine follow-up should occur every 3-6 months with specialists familiar with cystinosis management. Regular monitoring includes kidney function tests, growth assessment, eye examinations, and endocrine evaluations.

Parents should contact healthcare providers for medication adherence difficulties, as consistent treatment is crucial for preventing disease progression.

Regional context

While specific prevalence data for the Caucasus region is limited, cystinosis has been reported in populations worldwide with some regional variations in carrier frequency. Consanguineous marriages in certain communities may increase local prevalence.

We invite healthcare professionals and researchers in Georgia, Armenia, and Azerbaijan to contribute their experiences with cystinosis diagnosis and management to Global Medical Journal to enhance regional understanding of this condition.

Research and clinical trials

Current research focuses on improving cysteamine formulations, developing new cystine-depleting agents, and investigating gene therapy approaches. Stem cell therapy and tissue engineering for kidney replacement are areas of active investigation.

Clinical trials are evaluating extended-release cysteamine formulations, combination therapies, and novel treatment approaches. The Cystinosis Research Foundation funds significant research initiatives worldwide.

Patients and families can find current clinical trials at ClinicalTrials.gov using the search term “cystinosis.” Participation in research studies contributes to advancing treatments and potentially accessing experimental therapies.

Frequently asked questions

Is cystinosis curable?

Currently, there is no cure for cystinosis, but treatment with cysteamine can significantly slow disease progression and improve long-term outcomes when started early and maintained consistently.

How is cysteamine taken?

Cysteamine must be taken every six hours around the clock, including nighttime doses. The medication works best on an empty stomach and requires strict adherence to maintain therapeutic cystine depletion.

Can people with cystinosis have children?

Many males with cystinosis experience infertility, but some women can become pregnant with careful medical management. Genetic counseling is essential since children will be carriers or potentially affected.

What foods should be avoided?

There are no specific dietary restrictions for cystinosis, but patients may need nutritional supplements to replace losses from kidney dysfunction. Adequate hydration is particularly important.

Will my child need a kidney transplant?

With early and consistent cysteamine treatment, kidney transplantation can often be delayed or prevented. However, some patients may eventually require transplantation despite treatment.

Support and resources

• Cystinosis Research Foundation – Leading patient organization funding research and providing family support
• Orphanet – European database of rare diseases and orphan drugs
• National Organization for Rare Disorders (NORD) – Patient advocacy and information
• EURORDIS – European alliance of rare disease organizations
• WHO Rare Diseases – World Health Organization resources

Related conditions

• Fanconi Syndrome
• Chronic Kidney Disease
• Lysosomal Storage Disorders
• Hypothyroidism
• Growth Hormone Deficiency

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, Cystinosis Research Foundation, relevant clinical guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.